Axinn partner Chad Landmon spoke on a panel entitled, "Key Regulatory Issues in Biosimilars," at FDLI's Annual Conference in Washington, DC. Panelists discussed the latest regulatory issues surrounding FDA approval standards for biosimilars and the latest legal developments relating to the BPCIA's "patent dance."

Click here to access Chad's presentation.